Next, we monitored therapy induced modulation of ERK1/2 and AKT activation in CD90−veEPCAM+ve ovarian cancer cells isolated from malignant ascites of HGSOC patients with differential drug resistant status. Here, MAPK3 is linked to ovarian carcinoma.